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Even though some studies have reported the results of serial interferon-gamma release assays
(IGRAs) during isoniazid prophylactic treatment, serial results have not been reported after
rifampicin prophylaxis. A contact investigation was conducted after a tuberculosis (TB) outbreak
in an accommodation facility. The tuberculin skin test (TST) and the QuantiFERON-TB Gold In-
Tube (QFT-GIT) test were performed in 214 contacts with normal chest radiographs. Rifampicin
prophylaxis was initiated in TSTþ/QFT-GITþ subjects, and the QFT-GIT test was repeated upon
completion of 4 months of rifampicin treatment. Among the 214 contacts, the TST and QFT-GIT
test results were positive in 67.7% and 56.7%, respectively, and the agreement between the two
tests was fair-to-good (78.3%, kappaZ 0.55, p< 0.001). The QFT-GIT test was positive in 77%
(97/126) of contacts with positive TST results. Rifampicin prophylaxis was completed in 81
subjects with good compliance. Among 74 subjects with valid serial QFT-GIT test results, IFN-
g levels decreased in 97.3% (72/74) of the subjects and QFT-GIT test reversion (positive to nega-
tive) was achieved in 31 subjects (41.9%). Subjects without QFT-GIT test reversion had a signif-
icantly higher baseline TST induration sizes (18.3 4.8 vs. 14.9 3.4 mm, p< 0.01) and IFN-g
levels (18.6 17.9 vs. 3.2 7.5 IU/mL, p< 0.01) than the subjects with QFT-GIT test reversion.
Thus, IGRAsmay be useful in evaluating the therapeutic response to rifampicin prophylaxis in TB
contacts. However, considering that this was not a controlled study, a prospective controlled
study is needed to determine whether rifampicin prophylaxis truly affects QFT-GIT reversion.
ª 2009 Elsevier Ltd. All rights reserved.3010 3892; fax: þ82 2 3010 6968.
.kr (T.S. Shim).
9 Elsevier Ltd. All rights reserved.
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Tuberculosis (TB) is a significant global health issue. It is the
single most significant infectious cause of morbidity and
mortality worldwide, with approximately 1.7 million deaths
and 9.2 million new cases in 2006.1e3 Rapid diagnosis and
treatment of infectious patients are important components
of effective and efficient disease control and treatment in
developing countries. However, the treatment of latent TB
infection (LTBI) to prevent progression to active disease in
countries with low or intermediate TB burden is an essen-
tial public health strategic point for TB elimination.4,5
Small numbers of viable TB bacilli reside in an individual
with LTBI without obvious clinical symptoms. Individuals
with LTBI typically have normal chest radiographs (CXR),
and the tuberculin skin test (TST) has historically been the
only available diagnostic tool. Targeted TSTs for LTBI
treatment is a TB control strategy that selects subjects at
high risk of developing TB who would benefit from LTBI
therapy.6
Interferon-gamma (IFN-g) release assays (IGRAs) are
new tools for LTBI diagnosis and surveillance for a new TB
infection.7,8 IGRAs are in vitro assays based on IFN-g
production in response to early-secreted antigenic target
6-kDa protein (ESAT-6) and culture filtrate protein 10
(CFP-10). These antigens are specific to Mycobacterium
tuberculosis and are absent from all BCG vaccine strains
and most environmental mycobacteria.9,10 Commercial
IGRAs approved by the United States Food and Drug
Administration include the QuantiFERON-TB Gold test
(QFT-G; Cellestis Ltd., Carnegie, VIC, Australia), the
QuantiFERON-TB Gold In-Tube test (QFT-GIT; Cellestis
Ltd., Carnegie, VIC, Australia), and the T-SPOT.TB assay
(T-SPOT; Oxford Immunotec, Abingdon, UK). The QFT-GIT
test contains a third M. tuberculosis-specific antigen
(TB7.7) and uses an enzyme-linked immunosorbent assay
for detection of IFN-g responses.
The Centers for Disease Control and Prevention have
recommended use of the QFT-G test as an appropriate
substitute for the TST in contact investigations.11 The
National Institute for Health and Clinical Excellence (NICE)
guidelines recommend that positive TST reactors should be
tested by IGRAs as a two-stage strategy, if available.12
Combination testing is likely to reduce TB infection
screening costs compared to TST alone.13,14
The interpretation of serial IGRAs is challenging
because of non-specific variation, conversions, and
reversions. Previous studies have proposed that conver-
sions, reversions, and non-specific variations occur with
both serial IGRA testing and TSTs.15e20 In addition,
previous TST may boost the subsequent IGRA responses,
rendering the interpretation of serial IGRA results more
difficult.21 Some guidelines have supported serial IGRA
testing in place of TST, while others do not recommend
serial IGRA testing.22e25 Until now, in LTBI subjects, most
serial IGRA tests were performed in subjects taking
isoniazid prophylaxis.26,27 However, to our knowledge,
there are no reports evaluating serial IGRA tests after
rifampicin prophylaxis, even though one study evaluated
serial IGRA changes in subjects who took combined
isoniazid and rifampicin prophylaxis.17The incidence of active TB in South Korea is interme-
diate (88/10,000 per year) and BCG vaccination is manda-
tory at birth.1 Recently, a TB outbreak occurred in South
Korea, and due to the possibility of an isoniazid-resistant
index case, rifampicin prophylaxis was administered. We
evaluated serial QFT-GIT test results both at baseline and
upon completion of rifampicin prophylaxis for this
outbreak.
Materials and methods
Study design
Five residents of a group home for individuals with
intellectual disabilities (Seoul, South Korea) were diag-
nosed with active pulmonary TB in March 2007. The
index case was diagnosed with bacteriologically-
confirmed laryngeal and pulmonary TB. Initially,
a National TB Programme (NTP)-driven investigation of
the outbreak was initiated with serial CXR screening
only. Serial CXR screening was performed in March, April,
and May 2007 and active TB was diagnosed in 9, 9, and 1
contact, respectively. The TB patients were evenly
distributed in all classes. Acid-fast bacillus (AFB) smears
were positive in four patients and AFB cultures were
positive in two patients. The culture-positive patients
had DNA genotypes with different patterns. A
M. tuberculosis isolate was pan-susceptible to antibiotics
while another isolate was isoniazid-resistant.
Faced with the persistent development of TB, the NTP
performed TSTs and QFT-GIT tests for all residents and
teachers (nZ 214) in May 2007. For the analysis of the
results, individuals were divided into the following four
groups based on TSTs and QFT-GIT tests: TSTþ/QFT-GITþ,
TSTþ/QFT-GIT, TST/QFT-GITþ, and TST/QFT-GIT.
Rifampicin was prescribed for 4 months in individuals
with TSTþ/QFT-GITþ results, and most of the individuals
took the medication daily under direct observation due to
intellectual disabilities.
The QFT-GIT test was repeated upon completion of
rifampicin prophylaxis. CXRs were repeated every 3 months
for 1 year and every 6 months for the following year on all
contacts. Written informed consent was obtained from
study participants and guardians, and the study was
approved by the Institutional Review Board of the Korea
Institute of Tuberculosis.
Tuberculin skin test
A TST was performed using the Mantoux method and 2TU
PPD RT23 (Statens Serum Institute, Copenhagen, Denmark).
The induration size was measured after 48e72 h by expe-
rienced nurses, and a 10 mm induration size was set as the
cut-off value.
QuantiFERON-TB Gold In-Tube test
All participants were tested with the QFT-GIT test per the
manufacturer’s instructions. An IFN-g response to the
ESAT-6/CFP-10/TB7.7 mixture 0.35 IU/mL above the nil
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Figure 1 Flow diagram of contact investigation of infectious tuberculosis patients (nZ 246). TB: Tuberculosis, TST: tuberculin
skin test, QFT-GIT: QuantiFERON-TB Gold In-Tube.
Table 1 Clinical characteristics of 214 contacts with
normal chest radiographs.
Clinical characteristics Values (nZ 214)
Mean age, years (range) 41 (16e70)
Gender (Male:Female) 140:74
BMI, kg/m2, mean SD 21.8 3.3
History of previous anti-TB
treatment (%)
6/179 (3.4)
Presence of BCG scar (%) 135/201 (67.2)
TST induration size, mm,
mean SD (range)
12.4 7.2 (0e29)
TST induration size 10 mm (%) 130/192 (67.7)
Positive QFT-GIT (%) 115/203 (56.7)
Diabetes mellitus (%) 4 (1.9)
Rifampicin prophylaxis
completion (%)
81 (37.9)
BMIZ body mass index, TBZ tuberculosis, BCGZ bacille
Calmette-Gue´rin, TSTZ tuberculin skin test, IGRAZ interferon-
gamma release assay, QFT-GITZQuantiFERON-TB Gold In-Tube,
SDZ standard deviation.
450 S.H. Lee et al.control value (and 25% of the nil control) was considered
a positive result for the QFT-GIT test. If a response to M.
tuberculosis-specific antigens (corrected for the nil
control) was <0.35 IU/mL and the response to the
mitogen-positive control was >0.5 IU/mL, the response
was considered negative. Indeterminate results were
classified as nil-corrected IFN-g responses <0.35 IU/mL
and mitogen-positive control responses <0.5 IU/mL. QFT-
GIT test reversion was arbitrarily defined as a change from
a positive (0.35 IU/mL) to a negative (<0.35 IU/mL)
result.
Statistical analysis
All analyses were performed using SPSS software, version
12.0 (SPSS Inc., Chicago, IL, USA). Between-group
comparisons were made with t-test and ManneWhitney test
for variables. Concordance between test results from the
TST and QFT-GIT test was assessed using kappa coefficients.
All tests for significance were two-sided and statistical
significance was established at P values< 0.05.
Table 2 TST and QFT-GIT test results in 185 contacts.
TST Positive TST Negative
QFT-GIT Positive, n (%) 97 (77.0) 11 (18.6)
QFT-GIT Negative, n (%) 29 (23.0) 48 (81.4)
All 126 59
TST: tuberculin skin test, QFT-GIT: QuantiFERON-TB Gold
In-Tube
Table 4 Baseline predictors of QuantiFERON-TB Gold In-
Tube test reversion.
Reversion
(nZ 31)
Non-reversion
(nZ 43)
P
value
TST induration
size (mm)
14.9 3.4 18.3 4.8 <0.01
QFT-GIT IFN-g (IU/mL) 3.2 7.5 18.6 17.9 <0.01
TSTZ tuberculin skin test, QFT-GITZQuantiFERON-TB Gold
In-Tube.
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Clinical characteristics
A total of 246 subjects were screened with chest radio-
graphs and 214 contacts with normal chest radiographs
were included in the study (Fig. 1, Table 1). The mean age
was 41 years (range, 16e70 years) and the male-to-female
ratio was 65.4%:34.6%. A BCG scar was present in 135
subjects (67.2%).
The mean TST induration size was 12.4  7.2 mm (range,
0 e 29 mm). The TST and QFT-GIT tests were positive in
67.7% and 56.7% of the subjects, respectively. Both TST and
QFT-GIT test results were available for 185 participants,
and the agreement between both tests was fair-to-good
(78.3%, kappaZ 0.55, p< 0.001). Among 185 subjects,
positive TST results were detected in 126 (68.1%), and
positive QFT-GIT results among the subjects with positive
TST results were obtained in 77.0% of the subjects (97/126;
Table 2). Rifampicin prophylaxis was completed in 81
subjects with good drug compliance (Fig. 1).
Serial QuantiFERON-TB Gold In-Tube assay
A second round of QFT-GIT tests were performed in 75
subjects upon completion of 4 months of rifampicin
prophylaxis (Fig. 1). Excluding one subject with an inde-
terminate QFT-GIT test result, the QFT-GIT tests were
converted to negativity in 31 subjects (41.9%) and were
persistently positive in 43 subjects (58.1%). The baseline
clinical characteristics and test results of 74 subjects are
presented in Table 3. Follow-up CXRs were normal in allTable 3 Clinical characteristics of 74 contacts with valid
serial QFT-GIT test results after rifampicin prophylaxis.
Characteristics nZ 74
Mean age, years (range) 44 (27e70)
Gender (Male:Female) 59:15
History of previous
anti-TB treatment (%)
0
Diabetes mellitus (%) 2 (2.7)
Presence of BCG scar (%) 47 (63.5)
BMI, kg/m2, mean SD 21.9 3.1
Baseline TST induration
size 10mm (%)
74 (100.0)
Baseline QFT-GIT positive (%) 74 (100.0)
Reversion of QFT-GIT (%) 31 (41.9)
BCGZ bacille Calmette-Gue´rin, BMIZ body mass index,
TBZ tuberculosis, TSTZ tuberculin skin test, QFT-GITZ
QuantiFERON-TB Gold In-Tube, SDZ standard deviation.subjects. The IFN-g levels detected by the QFT-GIT test
were decreased in 72 subjects (97.3%) upon completion of
rifampicin prophylaxis compared with the baseline values,
and mean decrement extent of all subjects was
82.0 21.5%. Patients with persistently positive QFT-GIT
results had significantly higher baseline TST induration sizes
(18.3 4.8 vs. 14.9 3.4 mm, p< 0.01) and baseline IFN-g
levels by the QFT-GIT test (18.6 17.9 vs. 3.2 7.5 IU/mL,
p< 0.01) than patients with QFT-GIT test reversion (Table
4). IFN-g levels in the non-reversion group decreased in 41
of 43 subjects in paired comparisons (Fig. 2).Discussion
This is the first Korean study to compare the TST and QFT-
GIT results in a contact investigation of TB outbreak and the
first to serially check QFT-GIT tests in LTBI contacts who
took rifampicin prophylaxis. After rifampicin prophylaxis,
QFT-GIT test reversion occurred in 41.9% (31/74) of the
subjects and IFN-g levels decreased in almost all subjects,
suggesting that rifampicin prophylaxis may be effective in
the treatment of LTBI and the QFT-GIT test may be useful in
the evaluation of therapeutic responses in LTBI subjects.
In this study, TSTs and QFT-GIT tests were used for the
diagnosis of LTBI and the selection of candidates for LTBI
treatment. Twenty-three percent (29/126) of the subjects
with a positive TST and a negative QFT-GIT test result
avoided unnecessary prophylactic LTBI treatment by addi-
tional QFT-GIT test to the TST. The NICE guidelines
recommend prophylactic treatment for IGRA-positive indi-
viduals tested from a TST-positive population. In this study,
nearly 80% of TST-positive subjects demonstrated positive
QFT-GIT test results, whereas in other studies the propor-
tion of IGRA-positive subjects among the TST-positive
population was about 7.6%e50%.28e31 The high positive
QFT-GIT test results among TST-positive subjects in this
study may be due to prolonged close contact with infec-
tious TB patients. Among the 11 contacts with baseline
TST-/QFT-GITþ results, nobody was progressed to active TB
during the mean time of 23.9 months for follow-up.
There is not a generally approved definition of QFT-GIT
test reversion.16,32 The reported IGRA reversion (positive to
negative) rates in active TB after treatment are quite
variable (from 5.5% to 81%).7,33,34 Regarding LTBI, the IGRA
reversion rate was 10% (1/10) after 4 months of isoniazid
treatment.35 After completion of 6 months of isonizid
treatment, IGRA reversion rates were 7.9% (3/38), 10.7%
(3/28), and 25.0% (7/28).15,27,36 However, Pai et al.32
Figure 2 Paired changes of interferon-gamma levels in QuantiFERON-TB Gold In-Tube tests after rifampicin prophylaxis in the
reversion group (A) and in the non-reversion group (B). The horizontal bold lines at pre- and post-treatment values represent the
mean interferon-gamma values (A: 3.16 7.49 and 0.11 0.08, B: 18.62 17.85 and 3.75 4.74).
452 S.H. Lee et al.described persistently elevated IFN-g responses 4 and 10
months after completion of 6 months of isoniazid treatment
among rural Indian health care workers. Compared with the
previous studies, LTBI was treated with rifampicin in our
study; the reversion rate was relatively high (41.9%) and
follow-up IFN-g levels decreased in almost all subjects with
a mean decrement of 82.0 21.5%, suggesting that rifam-
picin may be more effective in treating LTBI. Theoretically,
rifampicin is more effective than isoniazid in mycobacterial
subpopulations with short bursts of metabolic activity.37 In
a murine model, the prophylactic efficacy of 2e3 months of
rifampicin therapy was superior to 6 months of isoniazid
therapy in reducing the burden of M. tuberculosis in splenic
cultures.38 Wilkinson et al.17 also reported that the mean
number of IFN-g spot-forming cells decreased after 82 days
of treatment with isoniazid and rifampicin in 16 LTBI
subjects, suggesting that the rifampicin-containing regimen
may be superior to isoniazid alone in inducing the reduction
of IFN-g levels during and after treatment. However, the
interpretation of serial IGRA test results should be viewed
with caution because there are huge within-subject vari-
abilities, especially in serial testing, and boosting of T cell
IFN-g responses following a TST.21
In this study, we could not identify the reasons why
subjects without QFT-GIT test reversion had a significantly
higher baseline TST induration size and IFN-g level than the
subjects with QFT-GIT test reversion. The subjects with
higher baseline TST induration size and IFN-g level may
require long interval to get the IFN-g under the cut-off
level. In order to confirm this, serial repeated QFT-GIT tests
are mandatory. Or, the subjects with higher baseline values
may need longer LTBI treatment for QFT-GIT reversion,
otherwise some of the higher reversion rate in the subjects
with lower baseline values may be caused by the non-
specific variations around the cut-off value in this group.
This study had some limitations. The number of partic-
ipants was small and serial IFN-g responses were measuredonly in rifampicin-treated contacts without control
subjects (no treatment or isoniazid treatment).
In conclusion, 77% of contacts with positive TST results
were QFT-GIT-positive, and QFT-GIT test reversions were
achieved in 41.9% of the subjects (31/74) after 4 months of
rifampicin treatment. The serial test results suggest the
possibility that the QFT-GIT test may be useful to monitor
the response to rifampicin prophylaxis. Further controlled
studies with more participants and long-term follow-up are
required to clarify these issues.
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